Navigation Links
Moussa B.H. Youdim wins the 2010 ECNP Lifetime Achievement Award
Date:9/2/2010

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Moussa B. H. Youdim as the recipient of the 2010 ECNP Lifetime Achievement Award in recognition of his innovative and lasting contribution to the area of neurodegenerative diseases and neuropsychiatric drug development. The ECNP Lifetime Achievement Award is presented biennially and recognises significant and lasting impact on the field of neuropsychopharmacology. The award is accompanied by a prize of 20,000.

Moussa B. H. Youdim, born in 1940 in Teheran, is Finkelstein Professor of Life Sciences and at Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology, Haifa, Israel. He is also founder and Director of the Eve Topf and U.S. National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Teaching, an independent extension of the Department of Pharmacology dedicated to advancing the understanding of neuropsychiatric disorders.

"With regard to current treatment standards based on symptom control, innovative neuroprotective therapies are needed in the common neurodegenerative disorders," he emphasised on the occasion of the 23rd ECNP Congress in Amsterdam, the Netherlands. Moussa Youdim has gained a worldwide reputation for his work in addressing this need in Parkinson's disease and Alzheimer's disease over nearly 50 years of highly productive activity.

He is especially known for his key role in establishing the importance of the monoamine oxidase enzymes, which are central to the metabolism of neurotransmitters such as dopamine, noradrenaline and serotonin, and the connection between these enzymes and abnormal brain iron metabolism. He has also pursued this research into the clinic, with the development of novel treatments for neurodegenerative diseases. "A current challenge for drug discovery designed for complex brain disorders such as Parkinson's or Alzheimer's disease is to look for multimodal drugs with a disease modifying effect," said Youdim.

Presenting the award at the 23rd ECNP Congress in Amsterdam, the chairman of the ECNP Award Jury 2010, Tomas Hkfelt of the Karolinska Institute in Stockholm, highlighted Youdim's scientific discoveries and their public health implications. "Demographic changes in Europe are making Parkinson's and Alzheimer's an increasing public health concern. Moussa Youdim's contribution to our understanding and better treatment of these conditions has been lasting and significant. We congratulate him on this well-deserved award."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
431-405-5734
European College of Neuropsychopharmacology
Source:Eurekalert

Related biology news :

1. Study shows genes role in developing and maintaining cells key for a lifetime of memories
2. University of Washington professors lifetime efforts receive international recognition
3. Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award
4. Dian Donnai receives lifetime award in genetics from March of Dimes
5. Maverick green economist gets lifetime achievement award
6. Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life
7. Roberta A. Pagon receives lifetime award in genetics from March of Dimes
8. Carnegies Donald Brown receives lifetime achievement award from Society for Developmental Biology
9. A low dose of caffeine when pregnant may damage the heart of offspring for a lifetime
10. IOF Medal of Achievement for outstanding scientific contributions awarded to John A. Kanis
11. To close achievement gap, US must address major health risks for urban minority youth, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... and paralysis, today announced that it has submitted a 510(k) to the FDA, ... that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission ...
(Date:1/18/2017)... OF PRUSSIA, PA (PRWEB) , ... January 18, ... ... disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives ... AstraZeneca in engaging panel discussions to examine vital clinical research issues such as ...
(Date:1/18/2017)... Francisco, CA (PRWEB) , ... January 18, 2017 ... ... to report the publishing of the latest paper by its Science Editor, Dr. ... Microbiology (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
Breaking Biology Technology: